XVIVO granted method patent for STEEN Solution™ in USA
The United States Patent and Trademark Office (USPTO) has approved a third patent in the “Preservation and evaluation solution” family. This means that STEEN Solution™ and XPS™ have increased patent protection in the USA but also that XVIVO has patent protection for use of a wide variety of alternative perfusion solutions for organ perfusion and evaluation. The patent is valid until the end of 2022.
XVIVO Perfusion already has an approved product patent for STEEN Solution™ and a broader method patent in the USA. The patent that has now been approved extends XVIVO’s patent protection for the use of alternative solutions for perfusion and evaluation of organs before transplantation.
The company’s products STEEN Solution™, XPS™ and the accompanying single-use products have been approved by the FDA and are being launched in the USA. The American market is the largest in the world and accounts for just over 40 percent of the number of lung transplants performed.
“Extended patent protection for STEEN Solution™ in the American market is important in protecting the intangible assets we have built up over many years in the USA, which is the absolute largest market for lung transplantation in the world. The method patent for STEEN Solution™ means that XVIVO strengthens its competitive position in the American market regarding warm perfusion and evaluation of organs outside the body,” says Dr Magnus Nilsson, CEO of XVIVO Perfusion AB.
March 20, 2015
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +46 31 788 21 59, email@example.com
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com
The information was submitted for publication on March 20, 2015 at 8:30 a.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the USA. The XVIVO share is listed on NASDAQ OMX First North and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: +46 31 788 21 50. Fax: +46 31 788 21 69.
E-mail: firstname.lastname@example.org. Website: www.xvivoperfusion.com